Clinical · Molecular biology
Integrated longitudinal analysis of ctDNA, radiologic response, and tumor volume reveals spatial and temporal heterogeneity in advanced melanoma
Summary
This study longitudinally analyzed circulating tumor DNA (ctDNA) in 42 patients with advanced melanoma treated with immune checkpoint inhibitors. ctDNA levels significantly correlated with radiological response according to RECIST 1.1 and total tumor volume, especially when measurements were temporally aligned. Although the discriminative performance for identifying progression was moderate, higher ctDNA thresholds demonstrated better specificity. The study also revealed marked heterogeneity in ctDNA shedding across metastatic sites, highlighting its potential as a complementary biomarker for disease monitoring.
Critical appraisal
This retrospective study suggests that ctDNA could serve as a complementary biomarker for longitudinal monitoring of advanced melanoma under immunotherapy. ctDNA levels are positively associated with radiological response (RECIST 1.1) and tumor volume, with stronger correlations for temporally aligned measurements (0-30 days, ρ = 0.56). The discriminative performance for progression is moderate (AUC = 0.69), with a sensitivity-specificity trade-off. ctDNA levels ≥ 25 mutant molecules/mL offer high specificity (≥ 83%) but low sensitivity (≤ 30%). These findings warrant prospective trials to validate ctDNA as a predictive or prognostic biomarker, potentially guiding therapeutic decisions or identifying early progression. Clinical impact could be seen in 3-5 years, by integrating ctDNA into surveillance algorithms.
The study utilized a UMI-based amplicon next-generation sequencing (NGS) assay to quantify ctDNA, targeting BRAF, EGFR, KRAS, NRAS, and PIK3CA genes. This technology allows for precise quantification of mutant molecules. A key discovery is the marked heterogeneity in ctDNA shedding across metastatic sites, with stronger associations in lymph node and peritoneal metastases, and limited detectability in lung, liver, and brain metastases. This biological heterogeneity has significant implications for the clinical interpretation of ctDNA, suggesting that the source of ctDNA can influence its correlation with overall tumor burden. For clinical validation, it would be essential to characterize the sensitivity and specificity of this approach in different metastatic contexts and standardize detection thresholds for diagnostic or monitoring applications.
The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology